The questions institutional investors are asking cannabis companies have changed. Revenue growth and license counts still matter, but lenders, acquirers, and sophisticated capital partners are now pressing on something the industry has spent a decade largely ignoring: the workforce. Who runs the company day to day, how decisions get documented, what happens if two or three key people walk - these are no longer soft concerns tucked into the back of a due diligence checklist. They're deal-shaping variables.

That's an uncomfortable exposure for an industry that built its compliance infrastructure around the product, not the people. Seed-to-sale tracking, METRC integrations, license renewal calendars, lab testing protocols, compliant packaging - cannabis operators have spent years getting that machinery tight. HR practices grew up around those priorities, not alongside them. Operators building in markets like New York, where regulatory complexity is layered on top of competitive pressure, increasingly rely on a cannabis retail platform for New York to manage the transactional and compliance side of their business - but workforce infrastructure rarely gets the same architectural attention. The result is a company that can document every gram from cultivation to point-of-sale and still struggle to produce a clean disciplinary record when an employment decision gets challenged.

The imbalance traces back to how the industry grew. Banking access was a crisis. License acquisition was a race. Capital was scarce and conditions were punishing - 280E tax exposure alone was enough to consume an operator's financial planning bandwidth for years. HR got built reactively as headcount scaled, not designed on purpose. That approach cost nothing under a regulatory structure that never asked about it. It gets expensive the moment a sophisticated buyer or lender starts running real diligence.

What Sophisticated Capital Actually Looks For

Marc Rodriguez, CEO of Green Leaf Business Solutions and a board member of the U.S. Cannabis Roundtable, has conducted HR and workforce assessments across cannabis companies ranging from small single-state operators to multi-location enterprises. The gaps he finds don't correlate with company size. Wage and hour compliance - overtime classification, break documentation, timekeeping accuracy - shows up as a recurring exposure regardless of whether the organization has 20 employees or 500. So does outdated HR documentation, including the disciplinary records that matter most when an employment decision is contested. Incomplete onboarding paperwork, I-9 compliance, personnel file management, and leave administration round out the pattern.

The issue isn't deliberate corner-cutting. It's infrastructure that never kept pace with growth. A cannabis retailer that scaled from two locations to ten in eighteen months rarely built an HR function designed for that size; it built one designed for where it started, then patched it forward. That distinction may be sympathetic, but it doesn't reduce the exposure when an investor's counsel is working through the files. Rodriguez's framing cuts to the point: what was once treated as an HR issue is now an enterprise risk issue. The audience has changed, and the standard has moved with it.

Darren Gleeman, who structures ownership transitions across cannabis through MBO Ventures, puts the mechanism plainly. Heavy founder dependence or high employee turnover rarely kills a deal. What it does is reshape the deal - through earnout structures, retention agreements, extended seller financing, or a longer diligence runway. The underlying question every acquirer is actually asking is whether the business keeps performing after ownership changes hands. If the answer depends on two or three irreplaceable people, that fragility doesn't appear on the P&L. It surfaces at the closing table, right when an operator has the least room to absorb a restructured offer.

The Structural Fragility That Licenses Can't Cover

There's a broader version of this problem worth naming directly. For most of cannabis's legal history, limited competition and scarce licenses created a protected market environment. Operators didn't have to prove they were efficient - they had to prove they were licensed and solvent. That's a low bar that rewarded survival and penalized nothing except outright noncompliance.

Federal rescheduling, if it proceeds, changes the cost of capital and the profile of who's willing to deploy it. Institutional lenders don't care about origin stories. They run standardized risk models, and those models treat workforce stability, documentation quality, and management depth as proxies for operational durability. An operator with a defensible license, growing top-line revenue, and zero bench below the founding team is not a safe bet by that standard - it's a concentration risk.

The cannabis companies that built infrastructure intentionally, rather than reactively, will look materially different in that environment. Not just cleaner in diligence, but actually more resilient. The ones that treated HR as a cost center to minimize will face a specific kind of problem: the numbers look fine until someone asks how the numbers get made.

Compliance as Floor, Culture as Ceiling

Brendan McKee, who leads Silver Therapeutics, argues the diligence-driven framing is necessary but not sufficient. Compliance protects a company from downside risk. It doesn't, on its own, build an organization worth betting on. His argument: if you choose not to invest in your people, you're choosing not to invest in your business. That principle has shaped how Silver Therapeutics managed its teams through cannabis retail's volatility - and it reframes what workforce management actually means for operators thinking about long-term value.

Here's the practical distinction. A company can clear a wage and hour audit, maintain clean I-9 files, and still have a workforce culture so thin that a buyer's retention assumptions fall apart in the first six months post-close. Compliance gets you past the legal exposure. Culture - compensation structure, career pathing, management quality, how disputes actually get resolved - determines whether the people a buyer or lender is underwriting stick around long enough to justify the bet. Those two things are related, but they're not the same, and conflating them is how operators end up building something that looks solid on paper and underperforms in practice.

For cannabis operators preparing for a raise, a refinancing, or an ownership transition, the actionable version of this is straightforward: start asking the questions a sophisticated investor would ask before that investor shows up. Audit wage and hour practices, not just product compliance. Build the HR documentation that makes employment decisions defensible. Assess founder dependence honestly and structure around it. None of this requires waiting for a deal to be on the table. The operators who run this work proactively are the ones whose diligence process looks like confirmation rather than discovery - and in a market where the cost of capital is only going to get more demanding, that difference is worth building for.